医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fabrinet to Present at J.P. Morgan Conference

2023年05月19日 AM05:15
このエントリーをはてなブックマークに追加


 

BANGKOK

Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced that its management will present at the J.P. Morgan 51st Annual Global Technology, Media and Communications Conference.

The Fabrinet presentation is scheduled for Wednesday, May 24, 2023 at 10:00 a.m. ET (7:00 a.m. PT). A live webcast, as well as a replay, will be accessible at https://investor.fabrinet.com/.

About Fabrinet

Fabrinet is a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and subsystems, automotive components, medical devices, industrial lasers and sensors. Fabrinet offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, advanced packaging, integration, final assembly and testing. Fabrinet focuses on production of high complexity products in any mix and any volume. Fabrinet maintains engineering and manufacturing resources and facilities in Thailand, the United States of America, the People’s Republic of China, and Israel. For more information visit: www.fabrinet.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005669/en/

CONTACT

Investor Contact:

Garo Toomajanian

ir@fabrinet.com

同じカテゴリーの記事 

  • COP28 UAEでザーイド・サステナビリティ賞受賞の11団体を表彰
  • 11位扎耶德可持续性奖获奖者在COP28 UAE期间举行的颁奖礼上获得表彰
  • Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH
  • Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery
  • FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer